In 2003, the FIP Dissolution Working group published a position paper on dissolution/drug release testing for special and novel dosage forms that represented the scientific knowledge in the field at that time. This position paper from 2003 has given impetus in the scientific, technical, and regulatory community.

Due to the rapid evolution of new practices and techniques for dissolution/drug release testing, the FIP Special Interest Group on Dissolution/Drug Release decided to revise the previous paper.

In the recently presented Workshop Report the following dosage forms are discussed: 

• Conventional solid drug products 
• Oral suspensions 
• Orally disintegrating tablets 
• Chewable tablets 
• Powders and granules 
• Thin dissolvable films  
• Chewing gums 
• Dermal systems (patches) 
• Topical systems (semisolid dosage forms)  
• Suppositories 
• Microparticulate formulations 
• Implants 
• Aerosols

Please find the extensive Report at "FIP/AAPS Joint Workshop Report: Dissolution/In Vitro Release Testing of Novel/Special Dosage Forms".

Author:
Dr. Günter Brendelberger
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)

Related GMP News
22/05/2013	Handling of APIs and Excipients - New Guidelines in Chapter 5 of EU GMP Guide
29/04/2013	New USP Chapter on Inhalation Drug Products
24/04/2013	Revision of the EU GMP Guide: EU Commission Proposal for Chapter 6 - Quality Control
17/04/2013	Quality Standards on Recovered Solvents in the Manufacture of Herbal Medicinal Products
13/02/2013	Laboratory Data Integrity in FDA Warning Letters 2012